Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
Molecular Weight:
425.46
Purity:
>99.99%
CAS Number:
[1609392-27-9]
Formula:
C20H19D3N8O3
Target:
Tyrosine Kinases|||Interleukin|||IFNAR|||JAK
T14687
* VAT and and shipping costs not included. Errors and price changes excepted